Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "OctPGMS pathway control state"

From Bioblast
ย 
Line 8: Line 8:


This substrate combination supports convergent electron flow to the [[Q-junction]].
This substrate combination supports convergent electron flow to the [[Q-junction]].
|info=[[MiPNet21.06 SUIT reference protocol]], [[SUIT reference protocol]]
|info=[[MiPNet21.06 SUIT RP]], [[SUIT reference protocol]]
}}
{{MitoPedia concepts
|mitopedia concept=SUIT state
}}
}}
::: ''More details'' ย 
::: ''More details'' ย 
Line 44: Line 41:
[[File:SUIT-Reference-Protocol 2.jpg|700px |SUIT RP2]]<br />
[[File:SUIT-Reference-Protocol 2.jpg|700px |SUIT RP2]]<br />
----
----
{{MitoPedia concepts
|mitopedia concept=SUIT state
}}

Latest revision as of 05:01, 19 July 2022


high-resolution terminology - matching measurements at high-resolution


OctPGMS pathway control state

Description

OctPGMS: Octanoylcarnitine & Pyruvate & Glutamate & Malate & Succinate.

MitoPathway control state: FNS

SUIT protocol: SUIT-001, SUIT-002, SUIT-015

This substrate combination supports convergent electron flow to the Q-junction.

Abbreviation: OctPGMS

Reference: MiPNet21.06 SUIT RP, SUIT reference protocol

More details
ยป FNS
ยป Additive effect of convergent electron flow
ยป Respiratory complexes - more than five
ยป OctPGM pathway control state
ยป Convergent electron flow

OctPMSL

FNS pathway in the LEAK state can be evaluated in the following SUIT protocols:

OctPMSP

FNS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:

OctPMSE

FNS pathway in the ET state can be evaluated in the following SUIT protocols:


SUIT RP1


SUIT RP2



MitoPedia concepts: SUIT state